Research peptides held in Australian stock, every lot tested by HPLC and mass spectrometry. For laboratory research use only.
Cart 0

BPC 157 vs TB500: Comparing Two Tissue Repair Research Peptides

Set BPC 157 vs TB500 next to each other and you find two strangers. They were never related, they just landed in the same field of repair research. The first, BPC-157, is cut from a gastric juice protein and runs to 15 residues, with most papers looking at nitric oxide and growth factor pathways. The second, TB-500, is a seven-residue fragment of thymosin beta-4, and its papers centre on actin and on cells moving into damaged tissue.

BPC 157 vs TB500, Compared Row by Row

BPC-157TB-500
Source proteinBody protection compound, isolated from human gastric juiceThymosin beta-4, a protein found in almost every cell
First described bySikiric group at the University of Zagreb, early 1990sGoldstein group, who isolated Tβ4 from calf thymus
SequenceGEPPPGKPADDAGLVAc-LKKTETQ (Tβ4 residues 17 to 23)
Residues and massAbout 1419 Da, 15 amino acidsAbout 889 Da, 7 amino acids
Leading proposed mechanismNitric oxide system, VEGFR2 and Akt-eNOS signalling, plus FAK-paxillin in fibroblastsBinding of G-actin, angiogenesis and cell migration
Models studiedGut, tendon, ligament and vascular endotheliumCardiac models, wound closure and the eye surface (full Tβ4)
Survives gastric juiceYes, according to published studiesNot shown
Evidence in humansThree small reports, all uncontrolledNone for the fragment, while full Tβ4 has reached phase 1 to 3
WADA listingCategory S0, Non-Approved SubstancesCategory S2, peptide hormones and growth factors
Formats at AminoLab10 mg BPC-157 vial, plus 500 mcg capsules10 mg TB-500 vial

Separate Histories Lead to Separate Research Questions

Any BPC 157 vs TB 500 discussion online treats them as a matched set, which hides how little the structures have in common. The BPC-157 story starts in a Croatian lab asking why stomach tissue is not destroyed by the acid it sits in. From ulcer models its literature spread into tendon, ligament and blood vessel work. Two papers anchor the musculoskeletal claims. One is the rat Achilles tendon study by Staresinic's team in the Journal of Orthopaedic Research (2003). The other is the tendon fibroblast work by Chang's team in the Journal of Applied Physiology (2011). Our guide to what BPC-157 is covers this history in more depth.

TB-500 arrived by a very different road. Thymosin beta-4 is a cytoskeletal protein, and its actin-binding motif was isolated and synthesised as a standalone fragment. Most of its supporting data actually belongs to the whole Tβ4 protein, the best-known example being a Nature paper from 2004 that used mouse heart cells. That gap between fragment and parent is unpacked in our TB-500 explainer.

TB 500 vs BPC 157, How Each One Is Thought to Work

A short way to frame it is that TB-500 research asks how cells travel to a site of damage, while BPC-157 research asks what then happens to the tissue and its blood vessels. Cells cannot crawl anywhere until their actin is rebuilt, and Tβ4 is one of the proteins that holds free G-actin in reserve. The BPC-157 papers point elsewhere. A 2017 report from Hsieh's group in the Journal of Molecular Medicine linked it to higher VEGFR2 levels, other work ties it to nitric oxide signalling, and fibroblast studies describe more outgrowth and movement through the FAK and paxillin route.

One point of overlap stands out. Both peptides promote new blood vessel growth in models, which is part of the reason they are so often paired. That same property is the common theoretical worry about long-term safety, a topic explored in our BPC-157 safety review.

Capsules for BPC-157 Only, and the Reason Why

At the checkout, tb500 vs bpc 157 mostly comes down to format. Because the literature reports BPC-157 holding up in gastric juice, it belongs to a small group of peptides studied orally, and that is why our shelves carry a capsule version (500 mcg) next to the 10 mg vial. Nobody has demonstrated the same for TB-500, so the only TB-500 we sell is a lyophilized 10 mg vial. Both vials are 3 mL glass with rubber stoppers, ready for bacteriostatic water. For the arithmetic, use the BPC-157 calculator or the matching TB-500 calculator for each vial.

Two Single Vials or One Wolverine Blend

This choice shapes the order more than any other, and our advice stays the same. Any design that pits one peptide against the other, or that might alter one without touching the other, should start from two single vials. Freeze-drying two compounds in one vial sets their proportions for good, and you lose the ability to study either alone.

Reserve the Wolverine Blend (BPC-157 + TB-500) for protocols that already call for both compounds at a set ratio. Then the blend earns its place, with half the vials to mix, half the lot numbers to log and one certificate for both peptides. The combined 10 mg fill has its own tool, the BPC-157 and TB-500 blend calculator.

Two single vialsWolverine blend
Reconstitutions neededTwoOne
Peptide ratioYour choiceLocked when manufactured
Certificates suppliedA separate one for each compoundA single one for both
SuitsDose-response and comparison designsProtocols that already use the two together

How KLOW and GLOW Build on the Pair

Two bigger blends start from these same two peptides. GLOW comes in a 70 mg vial, pairing 50 mg of GHK-Cu with BPC-157 and TB-500 at 10 mg apiece, which means the copper peptide accounts for most of the contents. KLOW is an 80 mg vial that takes those three and adds KPV, the lysine-proline-valine tripeptide. The GHK-Cu gives both a blue colour.

The reasoning used for the Wolverine blend holds even more strongly here, because four compounds sharing a vial means four fixed ratios. KLOW and GLOW are a good fit for research that is already built on those precise combinations. When only the two tissue repair peptides are needed, separate vials or the Wolverine blend keep things simpler. A full comparison of the larger blends is in the GLOW vs KLOW guide.

Shop BPC-157, TB-500 or the Blend at AminoLab

The comparison above points straight to the right purchase. We ship all three from Australian shelves to laboratories that order online. Type the lot number from any vial into the COA library and the independent identity and purity report appears. Compare them side by side in the recovery peptide range, then put bacteriostatic water in the cart with them.

Regulatory Status and Research-Only Supply

No product containing either peptide is an approved medicine in Australia, and neither appears on the ARTG. BPC-157 moved into Schedule 4 of the Poisons Standard on 1 June 2024, with the detail set out in our BPC-157 legal status guide. AminoLab sells these peptides to labs for research alone. They are not for people or animals, and staff will not answer questions about dosing or stacking.

Frequently Asked Questions

What actually separates BPC 157 from TB 500?

Almost everything. Their parent proteins are unrelated and no part of the sequence matches. BPC-157 has 15 residues and comes from gastric juice, and gut and tendon models test it against VEGFR2, nitric oxide and fibroblast pathways. TB-500 has seven residues taken from thymosin beta-4 and is tested for actin binding and how cells move.

Is TB 500 or BPC 157 better for research?

There is no overall winner since the two answer different mechanistic questions. More papers study BPC-157 directly, and it tolerates gastric juice. TB-500 leans heavily on data from the complete thymosin beta-4 molecule. Choose by the pathway under investigation.

Two single vials, or the Wolverine blend?

Single vials whenever one peptide is compared with the other or could be adjusted alone, because nothing in a blend can be rebalanced. The Wolverine blend makes sense once a protocol fixes both at its ratio, and it cuts out a vial and a mixing step.

How does the Wolverine blend compare with KLOW?

Wolverine is the two-peptide option, with only BPC-157 plus TB-500 sharing a 10 mg fill. KLOW goes to four compounds by bringing in GHK-Cu and KPV, packed in 80 mg. GLOW sits between, with GHK-Cu, BPC-157 and TB-500 in 70 mg and KPV left out.

Where do Australian labs order these peptides?

Straight from the AminoLab online store. Our Australian warehouse holds the Wolverine blend, TB-500 as a 10 mg vial, and BPC-157 as either a 10 mg vial or a pack of 60 capsules. An independent lab analyses each lot and the label's lot number links to its report. Supply is limited to laboratory research, with no use in humans or animals.

Popular Research Peptides

BPC-157

10 mg vial, 60 capsules

From $69

GHK-Cu

50 mg vial, 100 mg vial

From $49

Bacteriostatic Water

3 mL, 3 mL + 1 syringe, 10 mL, 10 mL + 1 syringe, 30 mL, 30 mL + 1 syringe

From $9
Certificate of analysisEvery research peptide comes with the certificate for its lot, listed in the COA library.
Tested identity and purityIdentity confirmed by mass spectrometry and purity measured by HPLC on every batch.
Australian stockOrders pack and ship from Australia with tracked Australia Post delivery. See delivery information.
Adults 18+ onlySold for laboratory research use only, under our research use policy.

Research use onlyAminoLab supplies research compounds for laboratory and in-vitro use, not for human or animal consumption. By continuing you confirm you are 18 or older and buying for research.

Leave